A Conversation with Dr. Jason Sicklick
In this interview with researcher & surgical oncologist Dr. Jason Sicklick shares about his passion for SDH-deficient GIST research.
In this interview with researcher & surgical oncologist Dr. Jason Sicklick shares about his passion for SDH-deficient GIST research.
In a recent study, researchers at University of California San Diego School of Medicine identified new therapeutic targets that could lead to new treatment options for patients. The study, published in the February 18, 2021 online edition of Oncogene, found that specific cell-to-cell communication influences GIST biology and is strongly associated with cancer progression and metastasis.
The Phase One Foundation has awarded GIST Specialist Jason Sicklick a $500,000 grant to study GIST in a Temozolomide Phase II clinical trial.
Our Good News Holiday Campaign is the culmination of our year of "Time to Tell the Stories 2022." In this series, we celebrate the connections, the celebrations, the events and milestones that we’ve been privileged to be a part of this year. Dr. Jason Sicklick discusses his research in SDH-deficient GIST.
Dr. Ramesh Bulusu, Dr. John Glod & Dr. Jason Sicklick discussed GIST research updates and answered questions in this GIST Awareness Day 2023 presentation.
Dr. Jason SIcklick, UC San Diego Moores Cancer Center presented The Role of Surgery in GIST Treatment/Neoadjuvant & Adjuvant Therapy at Life Fest 2022 in New Orleans.
Dr. Jason Sicklick of Moores Cancer Center at UC San Diego dedicated his new research lab to the memory of GISTer Merak Melikian Hatounian.
Em um artigo publicado em 29 de setembro de 2020, na revista "JAMA Network Open", o Dr. Jason Sicklick, Moores Cancer Center, UCSD, e colegas relataram que o teste genético é custo-efetivo e benéfico para pacientes com GIST metastático recém-diagnosticados. .
En un artículo publicado el 29 de septiembre de 2020 en la revista “JAMA Network Open”, Dr. Jason Sicklick, Moores Cancer Center, UCSD y sus colegas informaron que las pruebas genéticas son costo efectivas y beneficiosas para los pacientes recién diagnosticados con GIST metastásico.
UC San Diego Health released a post today titled, "Genetic Testing Cost Effective for Newly Diagnosed GIST" discussing a new paper published in JAMA Network Open by Moores Cancer Center's Dr. Jason Sicklick and colleagues which covered genetic testing for GIST patients.
If you didn't find what you were looking for, try a new search!